Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Redditch, United Kingdom Clinical Trials

A listing of Redditch, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (10) clinical trials

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

Patients are dosed for a minimum of nine days with drug. Surgery or biopsy can then take place at any time between Day 10 and Day 21 (depending on when it can be scheduled), but must occur with 24 hrs following three consecutive treatment days. During the treatment period, safety ...

Phase

9.68 miles

Learn More »

The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of ...

Phase

9.73 miles

Learn More »

A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

The purpose of this study is test the safety and tolerability of BMS-986224 and its effects on the body in healthy subjects and subjects with chronic heart failure with reduced ejection fraction

Phase

9.82 miles

Learn More »

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. The current trial is composed of a standard dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each dose level depending on the occurrence of ...

Phase

9.96 miles

Learn More »

Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

This is an open label, randomized, multi-centre study in postmenopausal women with primary ER+ HER2- breast cancer. Patients will be randomised to an oral dose of 250 mg bd AZD9496 or 500mg fulvestrant i.m. administered on one occasion. Patients diagnosed with primary breast cancer who are scheduled for surgery with ...

Phase

9.96 miles

Learn More »

ADC-1013 First-in-Human Study

The purpose of this study is to determine whether ADC-1013 (an agonistic human monoclonal IgG1 anti-CD40 antibody) is safe and tolerable when administered intratumorally (as repeated injections directly into the tumor tissue) or intravenously (as repeated doses directly into a vein) in patients with advanced solid tumors.

Phase

9.97 miles

Learn More »

Biventricular Pacing in Hypertrophic Cardiomyopathy

SUBJECTS Forty Participants, who fufil the entry criteria, will be selected. These Participants will be recruited from Cardiomyopathy clinics run at two sites. These are the Cardiomyopathy Clinics at the Heart Hospital, University College London, and from the Queen Elizabeth Hospital, Birmingham. CONSENT Written informed consent will be obtained from ...

Phase

9.97 miles

Learn More »

WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer

Patients with head and neck cancer with high-risk features are at increased risk of relapse after surgery. Surgery, often followed by cisplatin chemotherapy and radiotherapy is currently the standard treatment offered. Whilst chemo-radiotherapy improves cure rates, outcomes remain poor, and treatment has a significant impact on quality of life. Chemotherapy ...

Phase

9.97 miles

Learn More »

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

This is a double-blind, placebo-controlled, dose escalation trial of DCR-PHXC in Normal Healthy Volunteers (NHVs) and patients with Primary Hyperoxaluria (PH). Once safety has been established in NHV, PH patients with a confirmed diagnosis of PH1 and PH2 will be enrolled across multiple dosing cohorts. The study design will allow ...

Phase

9.97 miles

Learn More »

A First-In-Human Study to Evaluate Safety Tolerability Reactogenicity and Immunogenicity of JNJ-64300535 a DNA Vaccine Administered by Electroporation-Mediated Intramuscular Injection in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed

The purpose of this study is to evaluate the safety, tolerability, and reactogenicity of escalating doses of JNJ-64300535 delivered via electroporation-mediated intramuscular injection in nucleos(t)ide analogs (NA)-treated chronic hepatitis B (CHB) participants.

Phase

9.97 miles

Learn More »